GSK, Alector to co-develop antibodies for neurodegenerative diseases
GlaxoSmithKline (GSK) and Alector have partnered to co-develop and commercialise two clinical stage monoclonal antibodies for neurodegenerative diseases. Under the deal, the companies will co-develop AL001 and AL101
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.